Key Events This Week
3 Aug: Technical momentum shifts to sideways with cautious outlook
4 Aug: Mojo Grade upgraded to Sell on technical improvements despite weak fundamentals
5 Aug: Technical momentum shifts back to sideways trend amid mixed indicators
6 Aug: Stock price declines amid bearish weekly MACD and RSI signals
7 Aug: Mildly bullish daily moving averages signal potential short-term momentum

Panacea Biotec Ltd Technical Momentum Shifts Amid Mixed Indicator Signals
2026-08-07 08:03:19Panacea Biotec Ltd has exhibited a subtle shift in its technical momentum, moving from a sideways trend to a mildly bullish stance, despite a complex array of mixed signals from key technical indicators. The stock’s recent performance and technical parameters suggest cautious optimism amid ongoing volatility in the Pharmaceuticals & Biotechnology sector.
Read full news article
Panacea Biotec Ltd Technical Momentum Shifts Amid Mixed Indicator Signals
2026-08-05 08:03:42Panacea Biotec Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a mildly bullish stance to a sideways trend. Despite a modest decline of 0.90% on 5 Aug 2026, the stock’s technical indicators reveal a complex picture of mixed signals, reflecting both bearish pressures and pockets of resilience amid broader market volatility.
Read full news article
Panacea Biotec Ltd Upgraded to Sell on Technical Improvements Despite Weak Fundamentals
2026-08-04 08:47:26Panacea Biotec Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 3 August 2026, driven primarily by a shift in technical indicators despite persistent fundamental weaknesses. The company’s stock has shown mild bullish signals technically, although financial trends and quality metrics remain concerning for investors.
Read full news article
Panacea Biotec Ltd Technical Momentum Shifts Amid Mixed Indicator Signals
2026-08-04 08:05:51Panacea Biotec Ltd has exhibited a subtle shift in its technical momentum, moving from a sideways trend to a mildly bullish stance, despite mixed signals from key technical indicators. The stock’s recent performance and technical parameters suggest cautious optimism amid a challenging pharmaceutical sector backdrop.
Read full news article
Panacea Biotec Ltd Technical Momentum Shifts Amid Mixed Market Signals
2026-08-03 08:01:36Panacea Biotec Ltd has experienced a notable shift in its technical momentum, moving from a mildly bullish stance to a sideways trend as of early August 2026. Despite a modest day gain of 1.74%, the stock’s technical indicators present a complex picture, with bearish signals dominating weekly charts while monthly indicators offer a more nuanced outlook. This article analyses the recent technical parameter changes, key momentum indicators, and their implications for investors navigating the Pharmaceuticals & Biotechnology sector.
Read full news articlePanacea Biotec Declines 4.39% Amid Technical Weakness and Selling Pressure
2026-08-01 16:11:12
Key Events This Week
27 Jul: Stock opens at ₹433.30, declines 1.67% amid broad market gains
28 Jul: Hits lower circuit at ₹414.75 following intense selling pressure
30 Jul: Downgraded to Strong Sell; technical momentum shifts to sideways
31 Jul: Technical momentum shifts mildly bullish despite price decline to ₹421.30

Panacea Biotec Ltd Technical Momentum Shifts Amid Mixed Indicator Signals
2026-07-31 08:01:28Panacea Biotec Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a sideways trend to a mildly bullish stance. Despite a recent day decline of 2.38%, the stock’s technical indicators present a complex picture, with mixed signals from MACD, RSI, Bollinger Bands, and moving averages, reflecting cautious optimism amid ongoing volatility.
Read full news article
Panacea Biotec Ltd Downgraded to Strong Sell Amid Technical and Fundamental Weaknesses
2026-07-30 08:14:26Panacea Biotec Ltd has been downgraded from a Sell to a Strong Sell rating as of 29 Jul 2026, reflecting deteriorating technical indicators and weak fundamental performance. The company’s Mojo Score has declined to 23.0, signalling heightened risk for investors amid sideways technical trends and flat financial results in Q4 FY25-26.
Read full news articleDetails Of Shares Dematerialized During July 2026 Under Regulation 74(5) Of The SEBI (Depositories And Participants) Regulations 2018
05-Aug-2026 | Source : BSEPlease find attached details of shares dematerialised during July 2026.
Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order
05-Aug-2026 | Source : BSEWe are delighted to inform you that the Company has received Letter of Award for supply of bivalent Oral Polio Vaccine (bOPV) to UNICEF in 10 and 20 dose presentation worth ~US$8.205 million (~Rs.78.24 Crore) in Calendar Year 2028.
Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 (SEBI LODR Regulations)
24-Jul-2026 | Source : BSEThe Companys wholly owned subsidiary Panacea Biotec Pharma Ltd. has received a Show Cause Notice (SCN) dated July 23 2026 from the office of the Assistant Commissioner Goods and Services Tax Delhi under Section 73 of Delhi Goods & Services Tax / Central Goods & Services Tax Act & Rules 2017 alleging total tax liability of Rs.4.06 Crore including interest tax and penalty on account of alleged excess claim of Input Tax Credit in the Annual Return filed for the Financial Year 2022-23. The requisite disclosure is attached herewith.
Corporate Actions
No Upcoming Board Meetings
Panacea Biotec Ltd has declared 75% dividend, ex-date: 19 Sep 11
No Splits history available
No Bonus history available
No Rights history available






